Abstract
Recent advances in radiotherapy technology now enable us to deliver a booster dose of radiation to small target fractions in a malignant tumor. To fully exploit this technology in cancer therapy, it is necessary to clarify the location and dynamics of radioresistant cells in heterogeneous tumor microenvironments. Tumor cells in which the transcriptional activity of hypoxia-inducible factor 1 (HIF-1) is extremely high are recognized as potential targets, because HIF-1 has been strongly associated with tumor angiogenesis, invasion, metastasis, and poor prognosis after radiation therapy. In this review, we focus on recent advances in our understanding of [1] the molecular mechanism underlying the regulation of HIF-1s transcriptional activity, [2] the influence of radiation-induced alterations of the tumor microenvironment on intratumor HIF-1 activity, [3] HIF-1-mediated tumor radioresistance, and [4] an optimal treatment protocol for the combination of a HIF-1 inhibitor and radiation therapy.
Keywords: Radiation Therapy, tumor hypoxia, tumor microenvironment, hypoxia-inducible factor 1 (HIF-1), reoxygenation, radioresistance, ROS, reactive oxygen species
Current Signal Transduction Therapy
Title: Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Volume: 5 Issue: 3
Author(s): Hiroshi Harada and Masahiro Hiraoka
Affiliation:
Keywords: Radiation Therapy, tumor hypoxia, tumor microenvironment, hypoxia-inducible factor 1 (HIF-1), reoxygenation, radioresistance, ROS, reactive oxygen species
Abstract: Recent advances in radiotherapy technology now enable us to deliver a booster dose of radiation to small target fractions in a malignant tumor. To fully exploit this technology in cancer therapy, it is necessary to clarify the location and dynamics of radioresistant cells in heterogeneous tumor microenvironments. Tumor cells in which the transcriptional activity of hypoxia-inducible factor 1 (HIF-1) is extremely high are recognized as potential targets, because HIF-1 has been strongly associated with tumor angiogenesis, invasion, metastasis, and poor prognosis after radiation therapy. In this review, we focus on recent advances in our understanding of [1] the molecular mechanism underlying the regulation of HIF-1s transcriptional activity, [2] the influence of radiation-induced alterations of the tumor microenvironment on intratumor HIF-1 activity, [3] HIF-1-mediated tumor radioresistance, and [4] an optimal treatment protocol for the combination of a HIF-1 inhibitor and radiation therapy.
Export Options
About this article
Cite this article as:
Harada Hiroshi and Hiraoka Masahiro, Hypoxia-Inducible Factor 1 in Tumor Radioresistance, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920229
DOI https://dx.doi.org/10.2174/157436210791920229 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From TGF-β to Cancer Therapy
Current Drug Targets Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety
Recent Patents on Anti-Cancer Drug Discovery Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors
Current Drug Targets Modulation of the Immune Response by Targeting Endothelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Birt-hogg-Dubé Syndrome Incidentally Identified in a Potential Liver Donor
Current Medical Imaging Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold
Medicinal Chemistry Physiology of Folic Acid in Health and Disease
Current Drug Metabolism Graphene Oxide: A Carrier for Pharmaceuticals and a Scaffold for Cell Interactions
Current Topics in Medicinal Chemistry Proteomic Analysis of Mitochondrial Proteins on the Mechanism of Apoptotic Under Amorphophallus konjac Tuber (KONJAC) Extracts in Gas tric Cancer Cell
Current Proteomics Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications
Anti-Cancer Agents in Medicinal Chemistry CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Proteins: A to Z
Protein & Peptide Letters IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Current Clinical Pharmacology